Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2018, 2018, roč. 13, č. 3, s. 222.